ReviewJournal of the renin-angiotensin-aldosterone system : JRAAS2023
Angiotensin-Converting Enzyme and Hypertension: A Systemic Analysis of Various ACE Inhibitors, Their Side Effects, and Bioactive Peptides as a Putative Therapy for Hypertension.
Review in Journal of the renin-angiotensin-aldosterone system : JRAAS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Antihypertensive drugs for hyperuricemia in patients with hypertension: a systematic review and network meta-analysis of Chinese trials.BMC cardiovascular disorders · 2025Pooled it
- Non-surgical Treatment and Prophylaxis of Capsular Contracture in Mammary Implants: A Systematic Review of Literature.Aesthetic plastic surgery · 2025Pooled it
- Impact of pulse pressure variability evaluated by visit-to-visit on heart failure events in patients with hypertension: insights from the SPRINT trial.European journal of medical research · 2024Trial
- Gut Luminal Exosomes in Young and Old Mice: Multi-Omic Characteristics and Regulation of Gut Permeability.Aging cell · 2026Article
- Adverse event of ACE inhibitors: A descriptive analysis of FAERS data.Journal of public health research · 2026Article
- Isoindolines and Isoindoline-1,3-diones as Nonpeptide ACE Inhibitors: AnACS medicinal chemistry letters · 2026Article
- Goat milk-derived bioactive peptides as a health promoter: an insight based on recent in silico studies.Food science of animal resources · 2026Review
- In Vitro Evaluation of ACE and DPP-IV Inhibitory, and GLP-1 Stimulation Activities of Collagen Hydrolysate Enriched in Tripeptides.Biomedicines · 2026Article
- Prospecting of Novel Angiotensin I-Converting Enzyme Inhibitory Peptides from Bone Collagen ofFoods (Basel, Switzerland) · 2026Article
- Harnessing meat byproducts for health: bioactive peptides to modulate gut microbiota and promote sustainability.Food chemistry: X · 2026Review
- Review
- Spinal cord neuromodulation for blood pressure control using low-intensity focused ultrasound.Scientific reports · 2025Article
- Analysis of Genetic Variants MTHFR C677T, ACE I/D, AT1R A1166C and eNOS 4a/b in the Context of Essential Hypertension Susceptibility.Biomedicines · 2025Article
- Polyphenol-RichPharmaceutics · 2025Article
- Genetic and epigenetic architectures of stroke: Insights from GWAS to precision medicine.Neurochemistry international · 2025Review
- Unveiling the Therapeutic Mechanisms of Chinese Herbs in Heart Failure: Integrating Network Pharmacology, Molecular Docking, and Simulation Analysis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Discovery of novel angiotensin-converting enzyme inhibitory peptides byRSC advances · 2025Article
- Associations between the atherogenic index of plasma and coronary heart disease in hypertensive patients: results from NHANES 2005-2018.BMC cardiovascular disorders · 2025Article
- Advanced lung cancer inflammation index as a predictor of all-cause and cardiovascular mortality among patients with hypertension in the US.BMC cardiovascular disorders · 2025Article
- Functional Foods Enriched With Bioactive Compounds: Therapeutic Potential and Technological Innovations.Food science & nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a major risk factor for heart attack, produce atherosclerosis (hardening of the arteries), congestive heart failure, stroke, kidney infection, blindness, end-stage renal infection, and cardiovascular diseases. Many mechanisms are involved in causing hypertension, i.e., via calcium channels, alpha and beta receptors, and the renin-angiotensin system (RAS). RAS has an important role in blood pressure control and is also involved in the metabolism of glucose, homeostasis, and balance of electrolytes in the body. The components of RAS that are involved in the regulation of blood pressure are angiotensinogen, Ang I (angiotensin I), Ang II (angiotensin II), ACE (angiotensin-converting enzyme), and ACE 2 (angiotensin-converting enzyme 2). These components provide for relevant therapeutic targets for the treatment of hypertension, and various drugs are commercially available that target individual components of RAS. Angiotensin receptor blockers (ARBs) and ACE inhibitors are the most popular among these drugs. ACE is chosen in this review as it makes an important target for blood pressure control because it converts Ang I into Ang II and also acts on the vasodilator, bradykinin, to degrade it into inactive peptides. This review highlights various aspects of blood pressure regulation in the body with a focus on ACE, drugs targeting the components involved in regulation, their associated side effects, and a need to shift to alternative therapy for putative hypertension treatment in the form of bioactive peptides from food.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.